Virax Issuance Of Capital Stock from 2010 to 2025

VRAX Stock  USD 1.69  0.23  11.98%   
Virax Biolabs Issuance Of Capital Stock yearly trend continues to be fairly stable with very little volatility. Issuance Of Capital Stock will likely drop to 200.07 in 2025. During the period from 2010 to 2025, Virax Biolabs Issuance Of Capital Stock regression line of annual values had r-squared of  0.04 and arithmetic mean of  1,243,147. View All Fundamentals
 
Issuance Of Capital Stock  
First Reported
2010-12-31
Previous Quarter
210.6
Current Value
200.07
Quarterly Volatility
3.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Virax Biolabs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virax Biolabs' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 88.1 K or Interest Expense of 28.3 K, as well as many indicators such as Price To Sales Ratio of 10.3, Dividend Yield of 0.0 or PTB Ratio of 0.26. Virax financial statements analysis is a perfect complement when working with Virax Biolabs Valuation or Volatility modules.
  
Check out the analysis of Virax Biolabs Correlation against competitors.

Latest Virax Biolabs' Issuance Of Capital Stock Growth Pattern

Below is the plot of the Issuance Of Capital Stock of Virax Biolabs Group over the last few years. It is Virax Biolabs' Issuance Of Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virax Biolabs' overall financial position and show how it may be relating to other accounts over time.
Issuance Of Capital Stock10 Years Trend
Pretty Stable
   Issuance Of Capital Stock   
       Timeline  

Virax Issuance Of Capital Stock Regression Statistics

Arithmetic Mean1,243,147
Geometric Mean147,853
Coefficient Of Variation266.76
Mean Deviation1,551,400
Median519,613
Standard Deviation3,316,168
Sample Variance11T
Range13.7M
R-Value0.21
Mean Square Error11.3T
R-Squared0.04
Significance0.44
Slope144,053
Total Sum of Squares165T

Virax Issuance Of Capital Stock History

2025 200.07
2024 210.6
2023 234.0
202213.7 M

About Virax Biolabs Financial Statements

Virax Biolabs investors use historical fundamental indicators, such as Virax Biolabs' Issuance Of Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virax Biolabs. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Issuance Of Capital Stock 210.60  200.07 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.